Professor Karin Jordan graduated from Martin Luther University of Halle-Wittenberg, Germany. Following a number of posts at the University Hospital Halle and Bernward Hospital, Hildesheim, she was appointed as a specialist in Internal Medicine and Haematology and Oncology at the University of Halle-Wittenberg. She was the vice executive director of the ethics committee at the University of Halle from 2009-2015. From 2017 to 2021 she was the leading senior physician of the Department of Haematology and Oncology at the University Hospital in Heidelberg, Germany. Since 2021 she is head of department at the Ernst von Bergmann Clinic in Potsdam, where she leads the Clinic for Haematology, Oncology and Palliative Medicine.

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel in 2009 and 2015, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Working group on Supportive Care in Oncology (AGSMO). 

Professor Jordan is a member of the ESMO Council and Chair of the Educational Committee and a member of the Leadership Generation Task Force. She is a Subject Editor for the Supportive Care section of the ESMO Clinical Practice Guidelines and also a member of the Guidelines Steering Committee. Since 2014, she serves as an Associate Editor of Annals of Oncology and since 2018 as a member of the Editorial Board of ESMO Open. She was previously a member of the ESMO Young Oncologist Committee and the ESMO Faculty Coordinator for Supportive and Palliative Care. Since 2013, she is the coordinator of the S3 Guidelines on Supportive Care within the Oncology Guideline Programme of the German Cancer Society

Professor Jordan has authored and co-authored more than 200 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

Declaration of interest: Dr. Jordan holds no shares in any drug company. She has received study grants, honoraria for consultancy, speaker and advisory role of Amgen, Art Tempi, Astra Zeneca, G1, Helsinn, Hexal/Sandoz, MSD, Mundipharma, Riemser, Roche, Shire (Takeda), Vifor and Voluntis.